You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury Resuscitation

    SBC: SYNZYME TECHNOLOGIES LLC            Topic: 102

    DESCRIPTION provided by applicant Traumatic brain injury TBI is a leading cause of morbidity and mortality especially when complicated by secondary insults such as hypotension Vulnerability of TBI patients to hypotension is well recognized and identifies a key need for new approaches The goal of this proposal is to develop to IND a neuroprotective hyper colloid oxygen therapeutic polynit ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. A high resolution and high DQE detector optimized for mammography using single shot bi directional tri contrast imaging

    SBC: SIGRAY, INC.            Topic: NIBIB

    DESCRIPTION provided by applicant X ray tricontrast imaging provides three different modes of contrast absorption contrast the mechanism behind how conventional medical X ray imaging equipment images phase contrast which provides up to X more contrast than absorption based contrast for soft tissue and scatter contrast which provides information of features at dimensions smaller than ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A user-friendly scalable microfluidic platform for enhanced neuron-cell culture

    SBC: Xona Microfluidics, Inc.            Topic: 101

    DESCRIPTIONprovided by applicantNeuron cell culture is widely used for studies in basic researchdrug discoveryand toxicity testingTraditional neuron cell culture approaches result in random growth of processes which prevent the study of their unique polarized morphologyOur goal is to provide robustuser friendlyand cost effective culture platforms to manipulate and access neurons and their subcellu ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms

    SBC: NeuroSigma, Inc.            Topic: 101

    DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Urocortin Gene Transfer for CHF a Paracrine Approach Using Intravenous AAV

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain safely and easily sufficient cardiac transgene expression Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery approaches that are cumbersome to apply Consequently we have considered the u ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Single Cell Analysis via Nanoscale Tip Enhanced Laser Ablation Mass Spectrometry

    SBC: Anasys Instruments Corp.            Topic: NIGMS

    DESCRIPTION provided by applicant The goal of the proposed Phase II STTR research is to develop an imaging system capable of detecting and identifying biomolecules in cells and tissue sections with sub cellular spatial resolution The system combines an atomic force microscope AFM with mass spectrometry MS analysis and utilizes a unique tip enhanced laser ablation TELA method developed in ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Enhancing Confidentiality of Research Files Based on Medicare Data

    SBC: ACUMEN LLC            Topic: NIA

    DESCRIPTION provided by applicant In the andquot Enhancing Confidentiality of Research Files Based on Medicare Dataandquot project Acumen LLC aims to expand the overall capabilities of researchers to use survey linked Medicare claims data Currently the process for obtaining approval from the Centers for Medicare andamp Medicaid Services CMS to access these files entails significant paper ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Developing small molecule inhibitors of TLR for treatment of rheumatoid arthritis

    SBC: DYNAVAX TECHNOLOGIES CORPORATION            Topic: NIAID

    DESCRIPTION provided by applicant Autoimmune diseases like rheumatoid arthritis RA develop when the immune response targets self antigens leading to inflammation and tissue destruction There is now considerable evidence that recognition of self nucleic acids through toll like receptors TLRs can contribute significantly to sterile inflammation and autoimmunity with the clearest example b ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma

    SBC: IGE THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTIONprovided by applicantAllergic asthma is a multi faceted inflammatory disease in the lungIgE and Thmediated inflammation play a critical role in extrinsic allergic asthmaOur labs have identified naturally processed IgE cytotoxic peptidesnECPon IgE producing cellswhich serve as CTL vaccineThe feasibility of using nECP with helper peptide PADRE as a universal IgE vaccineor vaccineto treat ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government